With respect to IHC analysis of the tumor tissues from patients with HER2-positive gastric cancer, our findings of elevated YAP and TEAD expression in tissues collected during disease progression following HER2-targeted therapies were derived from a limited number of paired biopsies. This evidence concerns the gene YAP1 and neoplasm.